FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978685727> ?p ?o ?g. }

• W2978685727 endingPage "v367" @default.
• W2978685727 startingPage "v367" @default.
• W2978685727 abstract "Abstract Background Tislelizumab, an investigational anti-PD-1 antibody, was engineered to minimize binding to FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Previous reports showed tislelizumab was generally well tolerated and had antitumor activity in patients (pts) with advanced solid tumours, including UC. Methods This phase 2 clinical trial (CTR20170071) assessed the safety, tolerability, and efficacy of tislelizumab (200 mg Q3W) in Asian pts with PD-L1+ UC previously treated with ≥1 platinum-containing therapy. Prior treatment with a PD-(L)1 inhibitor was not allowed. During screening, archival tissue or fresh biopsy from all pts was sent to a central laboratory for PD-L1 testing via the VENTANA SP263 IHC assay. Patients were considered PD-L1+ if ≥ 25% of tumor or immune cells had PD-L1 expression. The primary efficacy endpoint was ORR (RECIST v1.1), assessed by an independent review committee (IRC). Secondary efficacy endpoints included DoR, PFS, and OS; AE incidence and severity were secondary safety endpoints. Results Between 04 Jul 2017 and 28 Feb 2019, 113 pts received tislelizumab for a median of 15 weeks and were followed up for a median of 8 mo. Urinary bladder (n = 51) and renal pelvis (n = 31) were common primary tumor sites. Of 104 evaluable pts, a confirmed objective response was observed in 24 pts (ORR=23%, 95% CI: 15.4, 32.4), including 8 CR and 16 PR per IRC assessment. Median DoR per IRC was not reached at the time of protocol-defined analysis; 19/24 (79%) responders had ongoing responses at data cutoff. Median PFS and OS were 2.1 and 9.8 mo, respectively. Anemia (27%), decreased appetite (19%), and pyrexia (17%) were the only TRAEs occurring in > 15% of pts; anemia (7%) was the only grade 3-4 TRAE occurring in ≥ 5% pts. Four pts experienced a grade 5 AE considered related to disease progression but also possibly related to treatment (hepatic failure, n = 2; respiratory arrest, n = 1; renal impairment, n = 1). Conclusions Tislelizumab was generally well tolerated and demonstrated clinical activity in pts with PD-L1+ UC. Clinical trial identification CTR20170071. Editorial acknowledgement Stephan Lindsey, PhD, at OPEN Health Medical Communications (Chicago, IL). Legal entity responsible for the study BeiGene, Ltd. Funding BeiGene, Ltd. Disclosure X. Qiu: Full / Part-time employment: BeiGene. L. Zhang: Full / Part-time employment: BeiGene. W. Shen: Full / Part-time employment: BeiGene. All other authors have declared no conflicts of interest." @default.
• W2978685727 created "2019-10-10" @default.
• W2978685727 creator A5000239300 @default.
• W2978685727 creator A5000664175 @default.
• W2978685727 creator A5001597981 @default.
• W2978685727 creator A5018737199 @default.
• W2978685727 creator A5021242284 @default.
• W2978685727 creator A5027177307 @default.
• W2978685727 creator A5032547003 @default.
• W2978685727 creator A5039924898 @default.
• W2978685727 creator A5045936395 @default.
• W2978685727 creator A5054529993 @default.
• W2978685727 creator A5055635104 @default.
• W2978685727 creator A5059507084 @default.
• W2978685727 creator A5062284808 @default.
• W2978685727 creator A5063068704 @default.
• W2978685727 creator A5067643729 @default.
• W2978685727 creator A5070661025 @default.
• W2978685727 creator A5076184087 @default.
• W2978685727 creator A5078806904 @default.
• W2978685727 creator A5081156337 @default.
• W2978685727 creator A5088203524 @default.
• W2978685727 date "2019-10-01" @default.
• W2978685727 modified "2023-10-16" @default.
• W2978685727 title "First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma (UC) in Asian patients" @default.
• W2978685727 doi "https://doi.org/10.1093/annonc/mdz249.019" @default.
• W2978685727 hasPublicationYear "2019" @default.
• W2978685727 type Work @default.
• W2978685727 sameAs 2978685727 @default.
• W2978685727 citedByCount "6" @default.
• W2978685727 countsByYear W29786857272020 @default.
• W2978685727 countsByYear W29786857272021 @default.
• W2978685727 crossrefType "journal-article" @default.
• W2978685727 hasAuthorship W2978685727A5000239300 @default.
• W2978685727 hasAuthorship W2978685727A5000664175 @default.
• W2978685727 hasAuthorship W2978685727A5001597981 @default.
• W2978685727 hasAuthorship W2978685727A5018737199 @default.
• W2978685727 hasAuthorship W2978685727A5021242284 @default.
• W2978685727 hasAuthorship W2978685727A5027177307 @default.
• W2978685727 hasAuthorship W2978685727A5032547003 @default.
• W2978685727 hasAuthorship W2978685727A5039924898 @default.
• W2978685727 hasAuthorship W2978685727A5045936395 @default.
• W2978685727 hasAuthorship W2978685727A5054529993 @default.
• W2978685727 hasAuthorship W2978685727A5055635104 @default.
• W2978685727 hasAuthorship W2978685727A5059507084 @default.
• W2978685727 hasAuthorship W2978685727A5062284808 @default.
• W2978685727 hasAuthorship W2978685727A5063068704 @default.
• W2978685727 hasAuthorship W2978685727A5067643729 @default.
• W2978685727 hasAuthorship W2978685727A5070661025 @default.
• W2978685727 hasAuthorship W2978685727A5076184087 @default.
• W2978685727 hasAuthorship W2978685727A5078806904 @default.
• W2978685727 hasAuthorship W2978685727A5081156337 @default.
• W2978685727 hasAuthorship W2978685727A5088203524 @default.
• W2978685727 hasBestOaLocation W29786857271 @default.
• W2978685727 hasConcept C121608353 @default.
• W2978685727 hasConcept C126322002 @default.
• W2978685727 hasConcept C143998085 @default.
• W2978685727 hasConcept C159654299 @default.
• W2978685727 hasConcept C203014093 @default.
• W2978685727 hasConcept C2780352672 @default.
• W2978685727 hasConcept C2911057145 @default.
• W2978685727 hasConcept C3019882237 @default.
• W2978685727 hasConcept C31760486 @default.
• W2978685727 hasConcept C502942594 @default.
• W2978685727 hasConcept C535046627 @default.
• W2978685727 hasConcept C71924100 @default.
• W2978685727 hasConceptScore W2978685727C121608353 @default.
• W2978685727 hasConceptScore W2978685727C126322002 @default.
• W2978685727 hasConceptScore W2978685727C143998085 @default.
• W2978685727 hasConceptScore W2978685727C159654299 @default.
• W2978685727 hasConceptScore W2978685727C203014093 @default.
• W2978685727 hasConceptScore W2978685727C2780352672 @default.
• W2978685727 hasConceptScore W2978685727C2911057145 @default.
• W2978685727 hasConceptScore W2978685727C3019882237 @default.
• W2978685727 hasConceptScore W2978685727C31760486 @default.
• W2978685727 hasConceptScore W2978685727C502942594 @default.
• W2978685727 hasConceptScore W2978685727C535046627 @default.
• W2978685727 hasConceptScore W2978685727C71924100 @default.
• W2978685727 hasLocation W29786857271 @default.
• W2978685727 hasOpenAccess W2978685727 @default.
• W2978685727 hasPrimaryLocation W29786857271 @default.
• W2978685727 hasRelatedWork W1970664244 @default.
• W2978685727 hasRelatedWork W2115347024 @default.
• W2978685727 hasRelatedWork W2470163336 @default.
• W2978685727 hasRelatedWork W3209180914 @default.
• W2978685727 hasRelatedWork W3212442606 @default.
• W2978685727 hasRelatedWork W4206524249 @default.
• W2978685727 hasRelatedWork W4246321156 @default.
• W2978685727 hasRelatedWork W4318967519 @default.
• W2978685727 hasRelatedWork W4353086468 @default.
• W2978685727 hasRelatedWork W4378529923 @default.
• W2978685727 hasVolume "30" @default.
• W2978685727 isParatext "false" @default.
• W2978685727 isRetracted "false" @default.
• W2978685727 magId "2978685727" @default.
• W2978685727 workType "article" @default.